[HTML][HTML] Antiviral activities of sotrovimab against BQ. 1.1 and XBB. 1.5 in sera of treated patients
T Bruel, LL Vrignaud, F Porrot, I Staropoli, D Planas… - medRxiv, 2023 - ncbi.nlm.nih.gov
Background Monoclonal antibodies (mAbs) targeting the spike of SARS-CoV-2 prevent
severe COVID-19. Omicron subvariants BQ. 1.1 and XBB. 1.5 evade neutralization of …
severe COVID-19. Omicron subvariants BQ. 1.1 and XBB. 1.5 evade neutralization of …
Assessment of neutralization susceptibility of Omicron subvariants XBB. 1.5 and BQ. 1.1 against broad-spectrum neutralizing antibodies through epitopes mapping
The emergence of new variants of the SARS-CoV-2 virus has posed a significant challenge
in developing broadly neutralizing antibodies (nAbs) with guaranteed therapeutic potential …
in developing broadly neutralizing antibodies (nAbs) with guaranteed therapeutic potential …
Evaluating in vivo effectiveness of sotrovimab for the treatment of Omicron subvariant BA. 2 versus BA. 1: a multicentre, retrospective cohort study
Background In vitro data suggested reduced neutralizing capacity of sotrovimab, a
monoclonal antibody, against Omicron BA. 2 subvariant. However, limited in vivo data exist …
monoclonal antibody, against Omicron BA. 2 subvariant. However, limited in vivo data exist …
[HTML][HTML] Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA. 2, BA. 4, and BA. 5 in patients receiving monoclonal antibodies
The emergence of Omicron sublineages impacts the therapeutic efficacy of anti-severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies (mAbs) …
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies (mAbs) …
Neutralizing monoclonal antibodies for the prevention of severe COVID-19: a retrospective study during Omicron BA. 1 variant surge
C Bartalucci, A Limongelli, LA Nicolini… - Journal of …, 2024 - Taylor & Francis
Among treatment options for Coronavirus disease 2019 (COVID-19), monoclonal antibodies
(mAbs) showed to be effective in preventing disease progression, but real-world data during …
(mAbs) showed to be effective in preventing disease progression, but real-world data during …
Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 omicron sub-lineages
The landscape of SARS-CoV-2 variants dramatically diversified with the simultaneous
appearance of multiple subvariants originating from BA. 2, BA. 4, and BA. 5 Omicron sub …
appearance of multiple subvariants originating from BA. 2, BA. 4, and BA. 5 Omicron sub …
Susceptibility of SARS-CoV-2 Omicron variants to therapeutic monoclonal antibodies: systematic review and meta-analysis
ABSTRACT SARS-CoV-2 Omicron variants contain many mutations in its spike receptor-
binding domain, the target of all authorized monoclonal antibodies (MAbs). Determining the …
binding domain, the target of all authorized monoclonal antibodies (MAbs). Determining the …
Preclinical safety and efficacy of a therapeutic antibody that targets SARS-CoV-2 at the sotrovimab face but is escaped by Omicron
J Kreye, SM Reincke, S Edelburg, LM Jeworowski… - Iscience, 2023 - cell.com
The recurrent emerging of novel viral variants of concern (VOCs) with evasion of preexisting
antibody immunity upholds severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
antibody immunity upholds severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
Molecular characterization of AZD7442 (tixagevimab-cilgavimab) neutralization of SARS-CoV-2 Omicron subvariants
TL Roe, T Brady, N Schuko, A Nguyen… - Microbiology …, 2023 - Am Soc Microbiol
Therapeutic anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
monoclonal antibodies (MAbs) provide immunosuppressed and vulnerable populations with …
monoclonal antibodies (MAbs) provide immunosuppressed and vulnerable populations with …
Sotrovimab therapy elicits antiviral activities against Omicron BQ. 1.1 and XBB. 1.5 in sera of immunocompromised patients
Antibodies effective against the recent Omicron sublineages are missing. By taking
advantage of a multi-centric prospective cohort of immunocompromised individuals treated …
advantage of a multi-centric prospective cohort of immunocompromised individuals treated …